Benefits

Image
Accu-Chek Instant showing the target range indicator
  1. Simpy clear The target range indicator visually helps patients to correctly interpret their blood glucose values1.
  2. Simply connected Bluetooth® enabled connectivity allows seamless transfer of blood glucose results to the mySugr® app. This makes it easier for patients to log their diabetes data and share with you ahead of consultations.
  3. Proven accuracy Fulfills ISO 15197:2013/EN ISO 15197:2015 and delivers even tighter 10/10 accuracy2, for results you can trust.
  4. Cost effective £5.95 per 50 test strips on the drug tariff*, €8.54 per 50 test strips on Primary Care Reimbursement Service (PCRS)**
Image
Accu-Chek Instant showing the target range indicator

Turn numbers into better outcomes<sup>3</sup>

The Accu-Chek Instant meter and mySugr app help your patients better self-manage their diabetes and provide you with the accurate data you need to make personalised treatment decisions for better therapy outcomes.2,3

Learn more about mySugr

What healthcare professionals say

Every aspect of the Accu-Chek Instant meter was designed with ease of use in mind. A survey found doctors, nurse educators and coaches agree<sup>4</sup>, with 91% of HCPs asked saying they'd recommend the Accu-Chek Instant meter.

Related products

Connect with a representative

Do you have questions, or are you ready to see a demo? Schedule a call, and we'll show you what we can do for you, your team, and your patients.

Request demo

Need help with your patients&#039; products?

From how-to-videos and FAQs to product manuals, our support resources are here for you and your patients every step of the way.

Product Support

Disclaimers

mySugr app: You must be at least 18 years old to register for the Accu-Chek Account. Please see the manual for intended use.

The Accu-Chek FastClix finger pricker is intended for patient self-monitoring by an individual person only. It must not be used to collect blood in a multipatient setting as it does not incorporate any features to guard against cross infection.

References

*Refers to UK Drug Tariff price as of June 2024. Please refer to www.nhsbsa.nhs.uk for updates.

**Refers to PCRS reimbursable items listed price as of June 2024. For updates please refer to www.sspcrs.ie/druglist/pub

1. Parkin CG et al. Use of an Integrated Tool for Interpretation of Blood Glucose Data Improves Correctness of Glycemic Risk Assessment in Individuals with Type 1 and Type 2 Diabetes. J Diabetes Sci Technol. 2017;11(1):74-82

2. Breitenbeck N, Brown A. Accuracy Assessment of a Blood Glucose Monitoring System for Self-Testing with Three Test Strip Lots Following ISO 15197:2013/EN ISO 15197:2015. J Diabetes Sci Technol. 2017 Jul;11(4):854-855. 

3. Debong F, Mayer H, and Kober J. Real-World Assessments of mySugr Mobile Health App. Diabetes Technol Ther. 2019;21(S2):S235– S240. 

4. Market research in 5 markets with 151 patients and 153 healthcare professionals. Roche Diabetes Care Whitepaper: The Accu-Chek® Instant meter is easy to use for SMBG from a healthcare professional and patient perspective; Results of a web-based online market research in 5 markets with 151 patients and 153 Healthcare Professionals. 22-July-2021. (Authors: Sigrid-Patricia Roehr, Julia Roetschke, Carola Niklaus).

BGM easier (Accu-Chek Instant Target Range Indicator): Parkin CG, et al. Use of an Integrated Tool for Interpretation of Blood Glucose Data Improves Correctness of Glycemic Risk Assessment in Individuals with Type 1 and Type 2 Diabetes. J Diabetes Sci Technol. 2016 Sep 12.

UK version of mySugr real world evidence: Ide C, et al. Real World Data analysis shows a significant improvement in glycaemic management when using a blood glucose monitor connected with a mobile health application in UK users with Type 2 Diabetes. Diabetes UK Professional Conference Poster Session, Liverpool, 26‑28 Apr 2023, Poster 198

Virtually pain-free: Jendrike N et al. Pain sensation at Fingertips and Palm by using different Blood Glucose Monitoring Systems. Diabetes Technology Meeting. San Francisco, 5-7 November 2009.